购物车
  • 全部删除
  • TargetMol
    您的购物车当前为空
筛选
已筛选:全部清除
TargetMol | Tags 通过 靶点 筛选
  • Apoptosis
    (1)
  • Chk
    (1)
  • Potassium Channel
    (1)
  • Others
    (2)
TargetMol | Tags 通过 货期 筛选
  • 现货
    (2)
  • 6-8周
    (1)
  • 8-10周
    (1)
抑制剂&激动剂
细分筛选
搜索结果
TargetMol产品目录中 "ml 277"的结果
筛选
搜索结果
TargetMol产品目录中 "

ml 277

"的结果
  • 抑制剂&激动剂
    4
    TargetMol | Inhibitors_Agonists
  • ML277
    ML-277, CID-53347902
    T33031401242-74-7
    ML277 (CID-53347902) 是一种有效的,选择性K(v)7.1 钾离子通道激动剂,EC50为270nM。
    • ¥ 248
    In stock
    规格
    数量
  • BML-277
    Chk2 Inhibitor II, C 3742, BML 277
    T2033516480-79-8
    BML-277 (C 3742) 是一种选择性的检测点激酶 2 抑制剂,IC50为 15 nM。
    • ¥ 155
    In stock
    规格
    数量
  • BML277 Acid
    T69163516480-80-1
    BML277 Acid is a metabolite of BML277 which is a selective checkpoint kinase 2 inhibitor.
    • ¥ 10600
    6-8周
    规格
    数量
  • P11149
    T38005164724-79-2
    P11149 is a competitive, BBB-penetarated weakly, orally active and selective inhibitor of AChE. P11149 exhibits an IC50 of 1.3 μM for rat BChE AChE. P11149, a Galanthamine derivative, demonstrates central cholinergic activity, behavioral efficacy and safety. P11149 is used in the study for Alzheimer’s disease[1]. P11149 is a GAL analog that is rapidly hydrolyzed in vivo to yield the potent AChE inhibitor, 6-DMG[1].P11149 exhibits greater s.c. bioavailability than p.o. [1].Oral P11149 in mice produces Sal, Lac and tremors at doses similar to those in rats, whereas 6-DMG, P1 1012 and GAL produces Sal and Lac at doses lower than those in rats[1].P11149 exhibits T1 2(el) of 2.4 h and Cmax of 585 ng mL in rat plasma[1]. [1]. G M Bores, et al. Pharmacological evaluation of novel Alzheimer’s disease therapeutics: acetylcholinesterase inhibitors related to galanthamine. J Pharmacol Exp Ther. 1996 May;277(2):728-38.
    • ¥ 12800
    8-10周
    规格
    数量